vs
科睿唯安（CLVT）与CARLISLE COMPANIES INC（CSL）财务数据对比。点击上方公司名可切换其他公司
CARLISLE COMPANIES INC的季度营收约是科睿唯安的1.7倍（$1.1B vs $617.0M），CARLISLE COMPANIES INC净利率更高（12.1% vs 0.5%，领先11.6%），CARLISLE COMPANIES INC同比增速更快（-4.0% vs -6.9%），科睿唯安自由现金流更多（$89.2M vs $-73.0M），过去两年科睿唯安的营收复合增速更高（-0.3% vs -14.8%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
卡莱尔公司是专业建筑产品供应商，聚焦于提升建筑能效与稳固性，面向商业建筑领域生产销售单层屋面产品、质保系统及配套配件，旗下设有卡莱尔建筑材料、卡莱尔防水技术两大业务板块，产品涵盖防潮材料、屋面防护层等多个品类。
CLVT vs CSL — 直观对比
营收规模更大
CSL
是对方的1.7倍
$617.0M
营收增速更快
CSL
高出3.0%
-6.9%
净利率更高
CSL
高出11.6%
0.5%
自由现金流更多
CLVT
多$162.2M
$-73.0M
两年增速更快
CLVT
近两年复合增速
-14.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $617.0M | $1.1B |
| 净利润 | $3.1M | $127.7M |
| 毛利率 | 66.8% | 34.5% |
| 营业利润率 | 6.7% | 17.1% |
| 净利率 | 0.5% | 12.1% |
| 营收同比 | -6.9% | -4.0% |
| 净利润同比 | 101.6% | -10.9% |
| 每股收益（稀释后） | $0.00 | $3.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTCSL
| Q1 26 | — | $1.1B | ||
| Q4 25 | $617.0M | $1.1B | ||
| Q3 25 | $623.1M | $1.3B | ||
| Q2 25 | $621.4M | $1.4B | ||
| Q1 25 | $593.7M | $1.1B | ||
| Q4 24 | $663.0M | $1.1B | ||
| Q3 24 | $622.2M | $1.3B | ||
| Q2 24 | $650.3M | $1.5B |
净利润CLVTCSL
| Q1 26 | — | $127.7M | ||
| Q4 25 | $3.1M | $127.4M | ||
| Q3 25 | $-28.3M | $214.2M | ||
| Q2 25 | $-72.0M | $255.8M | ||
| Q1 25 | $-103.9M | $143.3M | ||
| Q4 24 | $-191.8M | $162.8M | ||
| Q3 24 | $-65.6M | $244.3M | ||
| Q2 24 | $-304.3M | $712.4M |
毛利率CLVTCSL
| Q1 26 | — | 34.5% | ||
| Q4 25 | 66.8% | 33.8% | ||
| Q3 25 | 65.0% | 36.0% | ||
| Q2 25 | 67.2% | 37.3% | ||
| Q1 25 | 65.1% | 35.2% | ||
| Q4 24 | 65.7% | 36.1% | ||
| Q3 24 | 66.2% | 38.6% | ||
| Q2 24 | 67.2% | 39.2% |
营业利润率CLVTCSL
| Q1 26 | — | 17.1% | ||
| Q4 25 | 6.7% | 16.8% | ||
| Q3 25 | 7.1% | 21.8% | ||
| Q2 25 | 1.1% | 23.1% | ||
| Q1 25 | -3.5% | 16.8% | ||
| Q4 24 | -9.4% | 19.9% | ||
| Q3 24 | 3.5% | 23.7% | ||
| Q2 24 | -36.9% | 26.0% |
净利率CLVTCSL
| Q1 26 | — | 12.1% | ||
| Q4 25 | 0.5% | 11.3% | ||
| Q3 25 | -4.5% | 15.9% | ||
| Q2 25 | -11.6% | 17.6% | ||
| Q1 25 | -17.5% | 13.1% | ||
| Q4 24 | -28.9% | 14.5% | ||
| Q3 24 | -10.5% | 18.3% | ||
| Q2 24 | -46.8% | 49.1% |
每股收益（稀释后）CLVTCSL
| Q1 26 | — | $3.10 | ||
| Q4 25 | $0.00 | $3.06 | ||
| Q3 25 | $-0.04 | $4.98 | ||
| Q2 25 | $-0.11 | $5.88 | ||
| Q1 25 | $-0.15 | $3.20 | ||
| Q4 24 | $-0.27 | $3.76 | ||
| Q3 24 | $-0.09 | $5.25 | ||
| Q2 24 | $-0.46 | $14.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $329.2M | $771.3M |
| 总债务越低越好 | $4.3B | — |
| 股东权益账面价值 | $4.8B | $1.7B |
| 总资产 | $11.1B | — |
| 负债/权益比越低杠杆越低 | 0.89× | — |
8季度趋势，按日历期对齐
现金及短期投资CLVTCSL
| Q1 26 | — | $771.3M | ||
| Q4 25 | $329.2M | $1.1B | ||
| Q3 25 | $318.7M | $1.1B | ||
| Q2 25 | $362.6M | $68.4M | ||
| Q1 25 | $354.0M | $220.2M | ||
| Q4 24 | $295.2M | $753.5M | ||
| Q3 24 | $388.5M | $1.5B | ||
| Q2 24 | $376.4M | $1.7B |
总债务CLVTCSL
| Q1 26 | — | — | ||
| Q4 25 | $4.3B | $2.9B | ||
| Q3 25 | $4.4B | $2.9B | ||
| Q2 25 | $4.5B | $1.9B | ||
| Q1 25 | $4.5B | $1.9B | ||
| Q4 24 | $4.5B | $1.9B | ||
| Q3 24 | $4.6B | $2.3B | ||
| Q2 24 | $4.6B | $2.3B |
股东权益CLVTCSL
| Q1 26 | — | $1.7B | ||
| Q4 25 | $4.8B | $1.8B | ||
| Q3 25 | $4.9B | $2.0B | ||
| Q2 25 | $5.0B | $2.1B | ||
| Q1 25 | $5.0B | $2.2B | ||
| Q4 24 | $5.1B | $2.5B | ||
| Q3 24 | $5.5B | $2.8B | ||
| Q2 24 | $5.6B | $3.0B |
总资产CLVTCSL
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | $6.3B | ||
| Q3 25 | $11.2B | $6.5B | ||
| Q2 25 | $11.4B | $5.5B | ||
| Q1 25 | $11.5B | $5.5B | ||
| Q4 24 | $11.5B | $5.8B | ||
| Q3 24 | $12.0B | $6.5B | ||
| Q2 24 | $12.1B | $6.7B |
负债/权益比CLVTCSL
| Q1 26 | — | — | ||
| Q4 25 | 0.89× | 1.61× | ||
| Q3 25 | 0.90× | 1.45× | ||
| Q2 25 | 0.90× | 0.89× | ||
| Q1 25 | 0.90× | 0.87× | ||
| Q4 24 | 0.88× | 0.77× | ||
| Q3 24 | 0.84× | 0.83× | ||
| Q2 24 | 0.83× | 0.76× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $159.9M | — |
| 自由现金流经营现金流 - 资本支出 | $89.2M | $-73.0M |
| 自由现金流率自由现金流/营收 | 14.5% | -6.9% |
| 资本支出强度资本支出/营收 | 11.5% | 2.7% |
| 现金转化率经营现金流/净利润 | 51.58× | — |
| 过去12个月自由现金流最近4个季度 | $365.3M | $924.8M |
8季度趋势，按日历期对齐
经营现金流CLVTCSL
| Q1 26 | — | — | ||
| Q4 25 | $159.9M | $386.0M | ||
| Q3 25 | $181.1M | $426.9M | ||
| Q2 25 | $116.3M | $287.1M | ||
| Q1 25 | $171.2M | $1.8M | ||
| Q4 24 | $141.3M | $370.6M | ||
| Q3 24 | $202.9M | $312.8M | ||
| Q2 24 | $126.2M | $183.4M |
自由现金流CLVTCSL
| Q1 26 | — | $-73.0M | ||
| Q4 25 | $89.2M | $346.1M | ||
| Q3 25 | $115.5M | $393.4M | ||
| Q2 25 | $50.3M | $258.3M | ||
| Q1 25 | $110.3M | $-27.2M | ||
| Q4 24 | $59.1M | $334.0M | ||
| Q3 24 | $126.3M | $293.5M | ||
| Q2 24 | $60.3M | $158.5M |
自由现金流率CLVTCSL
| Q1 26 | — | -6.9% | ||
| Q4 25 | 14.5% | 30.7% | ||
| Q3 25 | 18.5% | 29.2% | ||
| Q2 25 | 8.1% | 17.8% | ||
| Q1 25 | 18.6% | -2.5% | ||
| Q4 24 | 8.9% | 29.7% | ||
| Q3 24 | 20.3% | 22.0% | ||
| Q2 24 | 9.3% | 10.9% |
资本支出强度CLVTCSL
| Q1 26 | — | 2.7% | ||
| Q4 25 | 11.5% | 3.5% | ||
| Q3 25 | 10.5% | 2.5% | ||
| Q2 25 | 10.6% | 2.0% | ||
| Q1 25 | 10.3% | 2.6% | ||
| Q4 24 | 12.4% | 3.3% | ||
| Q3 24 | 12.3% | 1.4% | ||
| Q2 24 | 10.1% | 1.7% |
现金转化率CLVTCSL
| Q1 26 | — | — | ||
| Q4 25 | 51.58× | 3.03× | ||
| Q3 25 | — | 1.99× | ||
| Q2 25 | — | 1.12× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 2.28× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 0.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Academia Government Group | $312.3M | 51% |
| Re Occurring Revenues | $114.1M | 18% |
| Life Sciences And Healthcare Group | $98.3M | 16% |
| Transactional Revenues | $97.1M | 16% |
CSL
暂无分部数据
